UK guidelines for the management of bone sarcomas
Abstract
This document is an update of the British Sarcoma Group guidelines published in 2010. The aim is to provide a reference standard for the clinical care of patients in the UK with bone sarcomas. Recent recommendations by the European Society of Medical Oncology, The National Comprehensive Cancer Network and The National Institute for Health and Care Excellence have been incorporated, and the literature since 2010 reviewed. The standards represent a consensus amongst British Sarcoma Group members in 2015. It is acknowledged that these guidelines will need further updates as care evolves. The key r...
Source: Clinical Sarcoma Research - May 3, 2016 Category: Cancer & Oncology Source Type: research
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients
Conclusions
Single agent ZA was associated with encouraging progression-free survival in four consecutive patients with metastatic osteosarcoma. Prospective trials of single agent ZA are warranted as protracted maintenance therapy in surgically incurable osteosarcoma relapsed or refractory to first line combination chemotherapy with radiographically measurable metastases. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - April 27, 2016 Category: Cancer & Oncology Source Type: research
Proof of principle for bevacizumab activity in desmoid-type fibromatosis
Conclusions
This is the first report on single agent bevacizumab in DF, which showed both, good tolerability and efficacy in our patient, thereby warranting future trials in DF. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - April 3, 2016 Category: Cancer & Oncology Source Type: research
Primary Kaposi’s sarcoma of the nasal cavity: a case report and review of the literature
Conclusions
A review of the literature revealed that only seven cases of primary Kaposi sarcoma of the nasal cavity have previously been published and only two of them presented in a patient not associated with the acquired immunodeficiency syndrome. Here, we report the third case where the primary manifestation of the Kaposi sarcoma was in the nasal cavity in a patient with an adequate immune system. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - March 17, 2016 Category: Cancer & Oncology Source Type: research
Primary Kaposi ’s sarcoma of the nasal cavity: a case report and review of the literature
Conclusions < /h3 > < p class= " a-plus-plus " > A review of the literature revealed that only seven cases of primary Kaposi sarcoma of the nasal cavity have previously been published and only two of them presented in a patient not associated with the acquired immunodeficiency syndrome. Here, we report the third case where the primary manifestation of the Kaposi sarcoma was in the nasal cavity in a patient with an adequate immune system. < /p > < /span > (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - March 16, 2016 Category: Cancer & Oncology Source Type: research
The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24–25, 2015. Workshop Report
This report summarizes the results of the 3rd Joint ENCCA-WP7, EuroSarc, EEC, PROVABES, and EURAMOS European Bone Sarcoma Network Meeting, which was held at the Children’s Cancer Research Institute in Vienna, Austria on September 24–25, 2015. The joint bone sarcoma network meetings bring together European bone sarcoma researchers to present and discuss current knowledge on bone sarcoma biology, genetics, immunology, as well as results from preclinical investigations and clinical trials, to generate novel hypotheses for collaborative biological and clinical investigations. The ultimate goal is to further improve therapy...
Source: Clinical Sarcoma Research - March 16, 2016 Category: Cancer & Oncology Source Type: research
Metastatic mesenteric dedifferentiated leiomyosarcoma: a case report and a review of literature
Conclusions
To our knowledge, this is the first report of a patient with metastatic mesenteric leiomyosarcoma who is in complete clinical and radiological long-term remission following very aggressive multimodal treatment; including intense poly-drug chemotherapy and without any demonstrable long-term side effects. Given the rarity of mesenteric leiomyosarcoma and lack of guidelines regarding oncological therapy, we suggest that multimodal therapy including aggressive chemotherapy, guided by a multidisciplinary team, is essential to achieve an optimal outcome. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - February 24, 2016 Category: Cancer & Oncology Source Type: research
Tumor volume is a better predictor of post-operative wound complications compared to tumor size in soft tissue sarcomas of the proximal lower extremity
Conclusions
Increase in tumor volume led to a higher risk of post-operative WCs. Assessing tumor volume may allow clinicians to better counsel patients on their risk of post-operative WCs. Tumor volume, as opposed to size alone, should be considered in future sarcoma outcome studies. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - February 22, 2016 Category: Cancer & Oncology Source Type: research
High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature
Abstract
Desmoid tumors are rare benign monoclonal fibroblastic tumors. Their aggressiveness is local with no potential for metastasis or dedifferentiation. Here we report on a 61-year-old patient who presented a locally advanced breast desmoid tumor diagnosed 20 years after post-operative radiotherapy for breast carcinoma. After 2 years of medical treatment, a high-grade undifferentiated pleomorphic soft tissue sarcoma arose within the desmoid tumor. Despite extensive surgery removing both tumors, the patient showed locoregional relapse by the sarcoma, followed by multimetastatic progression, then de...
Source: Clinical Sarcoma Research - November 30, 2015 Category: Cancer & Oncology Source Type: research
Alveolar rhabdomyosarcoma confined to the bone marrow with no identifiable primary tumour using FDG-PET/CT
Conclusion
Rhabdomyosarcoma can be limited to the bone marrow with no identifiable primary tumour. This case shows that the use of a bone marrow biopsy in suspected malignancies affecting the bone marrow is irreplaceable. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - November 19, 2015 Category: Cancer & Oncology Source Type: research
High-grade focal areas in low-grade central osteosarcoma: high-grade or still low-grade osteosarcoma?
Conclusion
Our data indicate that patients with a diagnosis of low-grade osteosarcoma where the high-grade (grade 3) component is lower than 50 % of the resected specimen, may not require chemotherapy, achieving high survival rates by means of complete surgical resection only. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - October 29, 2015 Category: Cancer & Oncology Source Type: research
Cytotoxic and targeted therapy for treatment of pseudomyogenic hemangioendothelioma
Abstract
Pseudomyogenic hemangioendothelioma (PMH) is a recently described, indolent vascular tumor that usually presents in the distal extremities. PMH typically has a multi-focal presentation and can involve several tissue planes including the dermis, subcutis, muscle, and bone. This soft tissue tumor predominantly affects men between 20 and 50 years of age. PMH tumors typically are resected but frequently recur locally; thus, more efficacious treatment options are needed. Herein, we report two cases of patients with PMH who were treated with systemic therapy. To the best of our knowledge, our report...
Source: Clinical Sarcoma Research - October 19, 2015 Category: Cancer & Oncology Source Type: research
Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
Conclusions
This is the first report detailing a response to treatment with sunitinib of a gastrointestinal stromal tumor with an uncommon exon 12 PDGFRA mutation. Based on the observed efficacy, GIST patients with this rare molecular subtype should be considered for sunitinib therapy. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - September 21, 2015 Category: Cancer & Oncology Source Type: research
Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?
Abstract
Over the past 15 years, irinotecan has emerged as an important agent for treating pediatric sarcoma patients. This review summarizes the activity noted in previous studies, and outlines current issues regarding scheduling, route of administration, and amelioration of side effects. Also discussed are new pegylated and nanoliposomal formulations of irinotecan and its active metabolite, SN-38, as well as future plans for how irinotecan may be used in combination with other conventional cytotoxic as well as targeted agents. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 28, 2015 Category: Cancer & Oncology Source Type: research
Retroperitoneal solitary fibrous tumor: surgery as first line therapy
Conclusion
Complete surgical excision is a viable treatment modality for retroperitoneal SFT leading to long term survival. Low recurrence rates would argue against the need for routine adjuvant radiation or chemotherapy. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 27, 2015 Category: Cancer & Oncology Source Type: research
